Webinar

The truth about AI in drug discovery: what the experts really think

11 March 2026

2:00pm

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.

Artificial intelligence (AI) is moving fast in early drug discovery, but results are mixed and real progress is not always visible. This roundtable brings together experts working with AI in active programmes to discuss how it supports target selection, generative molecule design and rapid hit discovery, as well as how they address complex and incomplete data in practical settings. The panel will also explore what is emerging next, including AI twins, model-driven decision making and workflow automation, with open insight into what is working and where challenges remain.

Attendees will gain practical insight into current capability, the gaps that still slow teams down and what to expect in the next phase of AI adoption.

You will learn: 

  • Where AI is delivering value in target selection, generative design and hit discovery today
  • What strong AI-enabled workflows look like in real discovery environments
  • Current limitations, roadblocks and what still needs solving
  • How AI twins, automation and model-driven decisions could change the next phase of R&D
  • What teams must have in place to make AI adoption successful

Reserve your place >>>

SPEAKERS

Dr Raminderpal Singh, Global Head of AI & GenAI Practice at 20/15 Visioneers

Dr. Raminderpal Singh is a highly recognised Key Opinion Leader in the TechBio industry and an Advisory Board Member for Drug Target Review, leveraging over 30 years of global experience to advise life sciences companies on building cost-efficient, IP-generating computational modeling systems to achieve novel biological breakthroughs. He currently leads the HitchhikersAI.org open-source community and is the CEO and co-Founder of Incubate Bio, a TechBio firm that uses in silico modeling to accelerate research and lower wet lab costs. His executive experience includes leadership roles at IBM Research in New York, where he led the go-to-market for IBM Watson Genomics Analytics, and as VP at Eagle Genomics Ltd; he holds a PhD, two books, and twelve issued patents, and was selected by EE Times in 2003 as one of the top 13 most influential people in the semiconductor industry.

Prof Jonathan Stokes, Assistant Professor of Biochemistry and Biomedical Sciences at McMaster University

Jon is an Assistant Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University. His research focuses on the development and application of leading-edge machine learning techniques for novel drug design tasks, with an emphasis on antibacterial agents. Jon is also the co-founder of Stoked Bio.

Dr Shantanu Singh, Principal Investigator and Senior Group Leader at the Broad Institute of MIT and Harvard

 

 

Dr Noor Shaker, Founder and CEO of SpatialX

 

 

 

Dr John Androsavich, General Manager of Ginkgo Datapoints

 

 

 

FAQs

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 11 March 14:00 2026 GMT. 

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.

[“tabbyending”]